Skip to Main Content

Paper Details

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Pharmacogenet Genomics
2
2018
Author NameAffiliation
Javier Ben??tezSpanish National Cancer Research Centre.
Javier Ben??tez
  • 1 - 2

Datasets

Release 1.2